The Only Product of Its Kind Backed By Level I Clinical Evidence

The result of the largest clinical study of the MTP joint to date. The only FDA-approved alternative to fusion.

93%

Reduction
in Pain1


Cartiva patients have experienced nearly the same substantial reduction in pain as fusion patients.

168%

Functional
Improvement2


Cartiva patients demonstrate long-lasting, substantial improvement in foot function.

50%

Improved Range
of Motion3


Cartiva doesn’t just preserve range of motion, but substantially increases it.

An Advanced Solution

Greater Patient
Satisfation

Pain relief, increased motion, and quicker recovery time mean happier patients.

40% Faster
than Fusion

The entire surgery only takes about 35 minutes.

Burns no
Bridges

The use of Cartiva does not prevent the implementation of fusion in the future.

Proven
Durability

Significant pain reduction, functional improvement, 96% implant survivorship at five years.

Interested in offering Cartiva to patients?

Reach out to find your local sales rep

Enter your name
Enter your email
Enter your zip code
Enter country name
Enter hospital with which you are affiliated

Footnotes

1 A substantial and clinically meaningful reduction in pain using the Visual Analog Scale (VAS) was experienced by subjects in the Cartiva group at every follow-up visit through 2 years. Cartiva subjects demonstrated a 93% reduction from a score of 68 at baseline to 5 at 2 years.

2 Functional activities were evaluated using the validated Foot and Ankle Mobility Measure (FAAM). Substantial improvement was observed for Cartiva subjects throughout the 2-year follow-up period with a 168% improvement observed in the sporting activities scale.

3 There was a substantial and clinically important improvement in active dorsiflexon motion in the Cartiva group, restoring motion to levels which are documented in the literature to be needed for normal walking gait while experiencing substantial reduction in pain.